Univariate analysis of TFS
. | . | . | Patients with feature . | . | Patients without feature . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Log rank . | P . | Median TFS (95% Cl) . | No. . | Median TFS (95% Cl) . | No. . | ||
| Binet stage | 18.05 | < .001 | — | — | — | — | ||
| A | — | — | 132 | 27 | — | — | ||
| B | — | — | 42 (21-63) | 27 | — | — | ||
| C | — | — | 36 (24-48) | 37 | — | — | ||
| β2-microglobulin level 3.5 mg/L or greater | 4.98 | .026 | 32 (15-49) | 26 | 58 (32-84) | 55 | ||
| TK level 10 IU/L or greater | 6.332 | .012 | 36 (17-55) | 39 | 77 (48-106) | 33 | ||
| Complex karyotype* | 25.72 | < .001 | 26 (15-37) | 24 | 106 (61-151) | 68 | ||
| CD38 | 17.31 | < .001 | 20 (7-33) | 13 | 88 (40-136) | 61 | ||
| 13q- single | 17.06 | < .001 | 106 (54-158) | 43 | 30 (18-42) | 46 | ||
| 11q- | 2.78 | .095 | 36 (0-80) | 12 | 58 (38-78) | 75 | ||
| +12 | 1.54 | .215 | 36 (23-49) | 11 | 48 (28-68) | 78 | ||
| 17p- | 7.35 | .007 | 28 (2-54) | 7 | 58 (34-82) | 82 | ||
| Balanced translocations | 19.59 | < .001 | 24 (18-30) | 21 | 77 (40-114) | 71 | ||
| Unbalanced translocations | 18.21 | < .001 | 26 (12-40) | 17 | 77 (39-115) | 75 | ||
| Translocations | 35.45 | < .001 | 24 (17-31) | 32 | 106 (74-138) | 60 | ||
| One translocation vs more than one translocation | 0.84 | .359 | 24 (14-34) | 18 | 24 (9-39) | 13 | ||
| Translocations stratified according to no. previous treatments | 17.95 | < .001 | — | — | — | — | ||
| Untreated patients | — | — | 26 (6-46) | 11 | 110 (NC) | 44 | ||
| Patients who had received one chemotherapeutic regimen | — | — | 24 (14-34) | 12 | 48 (22-74) | 13 | ||
| Patients who had received more than one chemotherapeutic regimen | — | — | 13 (0-41) | 8 | 228 (NC) | 2 | ||
. | . | . | Patients with feature . | . | Patients without feature . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Log rank . | P . | Median TFS (95% Cl) . | No. . | Median TFS (95% Cl) . | No. . | ||
| Binet stage | 18.05 | < .001 | — | — | — | — | ||
| A | — | — | 132 | 27 | — | — | ||
| B | — | — | 42 (21-63) | 27 | — | — | ||
| C | — | — | 36 (24-48) | 37 | — | — | ||
| β2-microglobulin level 3.5 mg/L or greater | 4.98 | .026 | 32 (15-49) | 26 | 58 (32-84) | 55 | ||
| TK level 10 IU/L or greater | 6.332 | .012 | 36 (17-55) | 39 | 77 (48-106) | 33 | ||
| Complex karyotype* | 25.72 | < .001 | 26 (15-37) | 24 | 106 (61-151) | 68 | ||
| CD38 | 17.31 | < .001 | 20 (7-33) | 13 | 88 (40-136) | 61 | ||
| 13q- single | 17.06 | < .001 | 106 (54-158) | 43 | 30 (18-42) | 46 | ||
| 11q- | 2.78 | .095 | 36 (0-80) | 12 | 58 (38-78) | 75 | ||
| +12 | 1.54 | .215 | 36 (23-49) | 11 | 48 (28-68) | 78 | ||
| 17p- | 7.35 | .007 | 28 (2-54) | 7 | 58 (34-82) | 82 | ||
| Balanced translocations | 19.59 | < .001 | 24 (18-30) | 21 | 77 (40-114) | 71 | ||
| Unbalanced translocations | 18.21 | < .001 | 26 (12-40) | 17 | 77 (39-115) | 75 | ||
| Translocations | 35.45 | < .001 | 24 (17-31) | 32 | 106 (74-138) | 60 | ||
| One translocation vs more than one translocation | 0.84 | .359 | 24 (14-34) | 18 | 24 (9-39) | 13 | ||
| Translocations stratified according to no. previous treatments | 17.95 | < .001 | — | — | — | — | ||
| Untreated patients | — | — | 26 (6-46) | 11 | 110 (NC) | 44 | ||
| Patients who had received one chemotherapeutic regimen | — | — | 24 (14-34) | 12 | 48 (22-74) | 13 | ||
| Patients who had received more than one chemotherapeutic regimen | — | — | 13 (0-41) | 8 | 228 (NC) | 2 | ||
To convert β2-microglobulin from milligrams per liter to nanomoles per liter, multiply milligrams per liter by 85.
TK indicates thymidine kinase; —, none; NC, not calculated.
Three or more chromosomal aberrations per sample.